Geode Capital Management
ACRV icon

Geode Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

Geode Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$472K Buy
265,241
+28,850
+12% +$49K ﹤0.01% 3626
2026
Q1 		$329K Buy
236,391
+38,168
+19% +$66.6K ﹤0.01% 3733
2025
Q4 		$478K Buy
198,223
+6,190
+3% +$13.5K ﹤0.01% 3599
2025
Q3 		$348K Buy
192,033
+27,671
+17% +$38.9K ﹤0.01% 3738
2025
Q2 		$196K Sell
164,362
-141,749
-46% -$195K ﹤0.01% 3883
2025
Q1 		$622K Buy
306,111
+4,722
+2% +$25.4K ﹤0.01% 3469
2024
Q4 		$1.81M Sell
301,389
-714
-0.2% -$5.19K ﹤0.01% 3165
2024
Q3 		$2.12M Sell
302,103
-6,290
-2% -$49.6K ﹤0.01% 3112
2024
Q2 		$1.79M Buy
308,393
+65,547
+27% +$528K ﹤0.01% 3152
2024
Q1 		$1.74M Buy
242,846
+53,646
+28% +$249K ﹤0.01% 3171
2023
Q4 		$931K Sell
189,200
-359
-0.2% -$1.9K ﹤0.01% 3382
2023
Q3 		$1.81M Buy
189,559
+11,106
+6% +$128K ﹤0.01% 3102
2023
Q2 		$2.31M Buy
178,453
+3,049
+2% +$36.9K ﹤0.01% 3063
2023
Q1 		$2.23M Buy
+175,404
New +$2.95M ﹤0.01% 2979

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management's ACRV Position: Q2 2026 in Review

Geode Capital Management increased its Acrivon Therapeutics (ACRV) stake by 12% in Q2 2026, buying an estimated $49K and bringing the position to 265,241 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #3626.

Geode Capital Management first reported a position in ACRV in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.31M in Q2 2023. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Geode Capital Management held 265,241 shares of Acrivon Therapeutics worth $472K as of Q2 2026.
  • Geode Capital Management bought 28,850 Acrivon Therapeutics shares in Q2 2026, an estimated $49K.
  • Acrivon Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3626 holding.
  • Geode Capital Management first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Geode Capital Management's Acrivon Therapeutics position peaked at $2.31M in Q2 2023.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.